Diagnostic antibodies and antigens for Epilepsy-related valproate (VPA) toxicity testing: Sodium valproate (VPA)


Valproate is a commonly used antiepileptic drug for the treatment of epilepsy and seizures. It is safe for use in both adults and children more than three years of age. Valproate toxicity can occur both accidentally and intentionally. Acute valproate overdose usually presents with CNS depression/encephalopathy, electrolyte abnormalities such as hypernatremia, elevated transaminase levels, hyperammonemia, and hepatoxicity. In patients with a severe overdose of valproate, patients can present with hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related hyperammonemic encephalopathy which may progress to coma and death. GENEMEDI developed the Sodium valproate (VPA) antigens and antibodies for the diagnosis of valproate toxicity based on ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.

Classification: VPA CZP



Sodium valproate (VPA)

Cat No. Species Biomarker Disease Cat No.of Antigen Bioactivity validation of Antigen Cat No.of Antibodies Bioactivity validation of Antibodies Order
GMP-SMT-VPA Human Sodium valproate (VPA) toxicity GMP-SMT-VPA-Ag01:
BSA-Sodium valproate (VPA);
GMP-SMT-VPA-Ag02:
OVA-Sodium valproate (VPA):
Competitive immunoassay-validated hapten-carrier conjugates [BSA-&OVA-Sodium valproate (VPA)], Sodium valproate (VPA) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in VPA level test of Epilepsy (toxicity) and related syndrome evaluation. GMP-SMT-VPA-Ab01:
Anti-Sodium valproate (VPA) mouse monoclonal antibody(mAb)
Human Sodium valproate (VPA) binding, in Competitive immunoassay validation, Elisa, lateral-flow tests, and other immunoassays in VPA level test of Epilepsy (toxicity) and related syndrome evaluation. Picture loading failed.



Nitrazepam, Clonazepam(CZP)

Cat No.SpeciesBiomarkerDiseaseCat No.of AntigenBioactivity validation of AntigenCat No.of AntibodiesBioactivity validation of AntibodiesOrder
GMP-SMT-202HumanNitrazepam, Clonazepam(CZP)anxiety, seizures, muscle spasmsGMP-SMT-202-Ag01:
BSA-Nitrazepam, Clonazepam(CZP)
GMP-SMT-202-Ag02:
OVA-Nitrazepam, Clonazepam(CZP)
Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Nitrazepam, Clonazepam(CZP), Nitrazepam, Clonazepam(CZP) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in CZP level test of Epilepsy (anxiety, seizures, muscle spasms) and related syndrome evaluation.GMP-SMT-202-Ab01:
Anti-Nitrazepam, Clonazepam(CZP) mouse monoclonal antibody(mAb)
GMP-SMT-202-Ab02:
Anti-Nitrazepam, Clonazepam(CZP) human monoclonal antibody(mAb)
Nitrazepam, Clonazepam(CZP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Nitrazepam, Clonazepam(CZP) antibodies in CZP level test of Epilepsy (anxiety, seizures, muscle spasms) and related syndrome evaluation.Picture loading failed.






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<